Hologic, Inc. (NASDAQ:HOLX) Receives Consensus Rating of “Hold” from Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have been given a consensus rating of “Hold” by the seventeen ratings firms that are presently covering the firm, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $84.62.

HOLX has been the topic of several recent research reports. Raymond James reiterated an “outperform” rating and issued a $90.00 price target (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Citigroup decreased their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday. Royal Bank of Canada cut their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Argus cut Hologic from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock.

Hologic Trading Up 0.7 %

Shares of HOLX opened at $62.50 on Friday. Hologic has a fifty-two week low of $61.70 and a fifty-two week high of $84.67. The firm has a market cap of $14.02 billion, a price-to-earnings ratio of 19.72, a PEG ratio of 2.14 and a beta of 0.97. The firm has a 50 day moving average price of $68.56 and a 200-day moving average price of $75.55. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts forecast that Hologic will post 4.28 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HOLX. Swedbank AB raised its position in shares of Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after buying an additional 306,562 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in Hologic by 55.1% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 7,449 shares of the medical equipment provider’s stock valued at $607,000 after acquiring an additional 2,645 shares during the last quarter. Stephens Inc. AR increased its stake in Hologic by 50.8% in the third quarter. Stephens Inc. AR now owns 6,445 shares of the medical equipment provider’s stock worth $525,000 after purchasing an additional 2,172 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Hologic by 27.4% during the third quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical equipment provider’s stock worth $164,000 after purchasing an additional 434 shares during the last quarter. Finally, Van ECK Associates Corp purchased a new stake in shares of Hologic during the third quarter valued at $725,000. Institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.